How long should you take Mitotane for adrenocortical cancer

Mitotane (Mitotane) is a targeted drug specifically used for adrenocortical cancer (ACC; adrenal cancer). It slows tumor growth and delays recurrence by selectively destroying adrenocortical cells and inhibiting the synthesis of adrenal hormones. Adrenocortical carcinoma is a rare endocrine malignancy with a fast progression and high recurrence rate, so mitotane plays a central role in adjuvant and maintenance therapy. Drug regimens are usually individualized based on plasma concentrations and patient tolerance rather than fixed cycles. Clinically, the ideal therapeutic blood drug concentration is usually between 14 and 20 mg/L. This range can ensure efficacy while minimizing toxicity.

In practical applications, the dose of mitotane will be gradually increased from a low dose until the target blood concentration is reached. During treatment, blood drug concentration needs to be monitored regularly, and metabolic indicators such as liver function, kidney function, blood lipids, and blood sugar should also be paid attention to. Common side effects include gastrointestinal discomfort, neurological reactions, dry skin, and abnormal liver function, but most side effects can be alleviated after dose adjustment and life management. Patients should strictly follow the doctor's instructions when taking medication, avoid increasing or decreasing the dosage on their own, and cooperate with the doctor for regular follow-up visits.

In addition, lifestyle and dietary management are equally important during mitotane treatment. Since drugs may cause loss of appetite and digestive problems, patients are advised to adopt a nutritionally balanced diet with small, frequent meals, while maintaining moderate exercise and psychological adjustment. Overseas guidelines also emphasize that long-term mitotane treatment should be combined with multidisciplinary management of endocrinology and oncology to ensure efficacy and safety.

Generally speaking, the taking time of mitotane needs to be individually formulated, combined with blood drug monitoring, clinical response and side effect management, in order to achieve the best therapeutic effect and extend the patient's recurrence-free period and survival period.

Reference materials:https://go.drugbank.com/drugs/DB00648